INTERNATIONAL PATENT: HANGZHOU HERVOR THERAPEUTICS CO., LTD, TCRCURE BIOPHARMA CORP., GUANGDONG TCRCURE BIOPHARMA TECHNOLOGY CO., LTD., TCRCURE HONG KONG LTD. FILES APPLICATION FOR "ENGINEERED TGFΒ RECEPTOR REPURPOSED FOR IL-9 SIGNALING AND USES THEREOF IN IMMUNE CELLS"

GENEVA, Sept. 28 -- HANGZHOU HERVOR THERAPEUTICS CO., LTD (RM111, 319 Shenjia Rd., Gongshu DistrictHangzhou, Zhejiang 310022), TCRCURE BIOPHARMA CORP. (P.O. Box 110087, Research Triangle Park, Durham, North Carolina), GUANGDONG TCRCURE BIOPHARMA TECHNOLOGY CO., LTD. (Building 12, No. 6 Nanjiang Second Road, Zhujiang Avenue, Nansha DistrictGuangzhou, Guangdong 511400), TCRCURE HONG KONG LTD. (Unit 2508A 25/F BANK OF AMERICA TOWER, 12 HARCOURT ROAD, CENTRALHong Kong) filed a patent application (PCT/CN2024/082584) for "ENGINEERED TGFBeta RECEPTOR REPURPOSED FOR IL-9 SIGNALING AND USES THEREOF IN IMMUNE CELLS" on Mar 20, 2024. With publication no. WO/2025/194364, the details related to the patent application was published on Sep 25, 2025.

Nota...